These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22533795)

  • 1. Emerging targets for the treatment of scleroderma.
    Leask A
    Expert Opin Emerg Drugs; 2012 Jun; 17(2):173-9. PubMed ID: 22533795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward personalized medicine in scleroderma: classification of scleroderma patients into stable "inflammatory" and "fibrotic" subgroups.
    Leask A
    J Invest Dermatol; 2012 May; 132(5):1329-31. PubMed ID: 22499038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research.
    Avouac J; Kowal-Bielecka O; Landewe R; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):629-34. PubMed ID: 18957486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors in the management of autoimmune disease.
    Shenoy P; Agarwal V
    Autoimmun Rev; 2010 May; 9(7):511-5. PubMed ID: 20149898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding systemic sclerosis through gene expression profiling.
    Pendergrass SA; Whitfield ML; Gardner H
    Curr Opin Rheumatol; 2007 Nov; 19(6):561-7. PubMed ID: 17917536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Pope J; Harding S; Khimdas S; Bonner A; ; Baron M
    J Rheumatol; 2012 Mar; 39(3):524-31. PubMed ID: 22247347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Egr-ly awaiting a "personalized medicine" approach to treat scleroderma.
    Leask A
    J Cell Commun Signal; 2012 Jun; 6(2):111-3. PubMed ID: 22350706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
    Shiwen X; Leask A; Abraham DJ; Fonseca C
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scleroderma -- news to tell.
    Eckes B; Hunzelmann N; Moinzadeh P; Krieg T
    Arch Dermatol Res; 2007 Jun; 299(3):139-44. PubMed ID: 17453220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.
    Greenblatt MB; Sargent JL; Farina G; Tsang K; Lafyatis R; Glimcher LH; Whitfield ML; Aliprantis AO
    Am J Pathol; 2012 Mar; 180(3):1080-1094. PubMed ID: 22245215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving pharmacotherapy of pulmonary fibrosis.
    Lota HK; Wells AU
    Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural remedies for scleroderma.
    Gaby AR
    Altern Med Rev; 2006 Sep; 11(3):188-95. PubMed ID: 17217320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.
    Roofeh D; Lescoat A; Khanna D
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):455-466. PubMed ID: 33054463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria to select molecular targets for anti-fibrotic therapy.
    Distler JH; Distler O
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v12-3. PubMed ID: 18784127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathways as novel therapeutic targets in systemic sclerosis.
    Trojanowska M; Varga J
    Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression in bronchoalveolar lavage cells from scleroderma patients.
    Luzina IG; Atamas SP; Wise R; Wigley FM; Xiao HQ; White B
    Am J Respir Cell Mol Biol; 2002 May; 26(5):549-57. PubMed ID: 11970906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.
    Walker KM; Pope J; ;
    J Rheumatol; 2011 Jul; 38(7):1326-8. PubMed ID: 21459952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pleomorphism of systemic sclerosis: are we ready for 'personalized medicine' in scleroderma?
    Steen VD
    Expert Rev Clin Immunol; 2011 Jul; 7(4):403-5. PubMed ID: 21790281
    [No Abstract]   [Full Text] [Related]  

  • 20. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.